Efineptakin alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Efineptakin alfa
DrugBank Accession Number
DB16395
Background

Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immunology, and infectious disease.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Efineptakin alfa
  • Hyleukin
  • NT-I7
  • Recombinant human IL-7-HYFC
External IDs
  • NT-I7

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
3K3WC6MT6P
CAS number
2026634-47-7

References

General References
  1. NeoImmuneTech: NT-I7 is a Unique T Cell Amplifier. [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2RecruitingTreatmentGastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)1
2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma AIDS Related / Kaposi’s sarcoma1
1RecruitingSupportive CareGliomas, Malignant / Lymphopenia1
1RecruitingTreatmentBladder Carcinoma / Breast Carcinoma / Colorectal Adenocarcinoma (CRC)1
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)2
1RecruitingTreatmentRecurrent Head and Neck Squamous Cell Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Oral Cavity Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Resectable Oropharyngeal Squamous Cell Carcinoma1
1WithdrawnTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2RecruitingTreatmentAny Advanced Solid Tumors / Breast Cancer (Triple Negative Breast Cancer (TNBC)) / Malignant Neoplasm of Pancreas / Microsatellite Stable (MSS) Colorectal Cancer (CRC) / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer / Small Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 23, 2020 16:12 / Updated on February 21, 2021 18:55